The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US
•18% of residential treatment admissions had MOUD in treatment plans•MOUD increased treatment completion 40% in short term residential treatment.•MOUD increased treatment retention 34% in short term residential treatment.•MOUD decreased treatment completion 26% in long term residential treatment.•MO...
Gespeichert in:
Veröffentlicht in: | Drug and alcohol dependence 2020-07, Vol.212, p.108067, Article 108067 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •18% of residential treatment admissions had MOUD in treatment plans•MOUD increased treatment completion 40% in short term residential treatment.•MOUD increased treatment retention 34% in short term residential treatment.•MOUD decreased treatment completion 26% in long term residential treatment.•MOUD did not significantly affect retention in long term residential treatment.
This study examines whether MOUD increases treatment completion and retention in both short-term (ST) and long-term (LT) residential programs using a national dataset.
Data were extracted from the 2015–2017 TEDS-D (Treatment Episode Dataset-Discharge) datasets for opioid using adults in ST (n = 87,296) and LT (n = 66,623) residential treatment. Primary outcome variables were treatment completion and retention (ST: length of stay >10 days; LT: >90 days). Logistic regression estimated the effects of MOUD on the probability of treatment completion and retention separately for ST and LT residential treatment, controlling for individual background characteristics.
Only 18% of clients in residential treatment programs had MOUD in their treatment plans. For ST residential treatment, MOUD was associated with a 40% increased likelihood of treatment completion (OR = 1.404) and 34% increased retention (OR = 1.337). For LT residential treatment, MOUD was associated with a 26% reduced likelihood of treatment completion (OR = 0.743) and no significant increase in retention. Post hoc analysis suggests insurance coverage may be influencing outcomes.
Despite MOUD being a standard of care for OUD, MOUD is particularly under-utilized in residential treatment. Further research should focus on how best to integrate MOUD within short-term residential treatment and to explore the potential viability of MOUD in long-term residential programs. Given the risk of overdose following residential treatment, for at least short-term residential programs, this setting may be advantageous for integrating psychosocial treatments with early MOUD engagement in a structured therapeutic environment as part of a long-term continuum of care recovery program. |
---|---|
ISSN: | 0376-8716 1879-0046 |
DOI: | 10.1016/j.drugalcdep.2020.108067 |